A method, primer set and kit thereof for respiratory syncytial virus whole genome sequencing

By combining specific targeted primers and multiplex amplification technology with a third-generation sequencing platform, the problems of data heterogeneity and human DNA contamination in respiratory syncytial virus whole genome sequencing have been solved, achieving efficient and sensitive whole genome coverage and typing.

CN119220743BActive Publication Date: 2026-05-29PEKING UNION MEDICAL COLLEGE HOSPITAL +1
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
CN202411640269.6
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-11-15
Publication Date
2026-05-29
Estimated Expiration
2044-11-15

Smart Images

  • Figure CN119220743B_ABST
    Figure CN119220743B_ABST
Patent Text Reader

Abstract

The application discloses a method, a primer group and a kit for whole genome sequencing of respiratory syncytial virus, and belongs to the technical field of DNA detection.The method comprises the following steps: S1, using first round amplification primers with sequences shown in SEQ ID NO.1 to SEQ ID NO.35 in table 1 to perform first round amplification with respiratory syncytial virus cDNA as a template; and S2, using second round amplification primers with sequences shown in SEQ ID NO.36 to SEQ ID NO.227 in table 2 to perform second round amplification with the first round amplification product as a template.The average length of data sequenced by the method is 0.8 kb, and the uniformity of respiratory syncytial virus coverage is greatly improved.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention belongs to the field of DNA detection technology, specifically relating to a method, primer set and reagent kit for whole genome sequencing of respiratory syncytial virus. Background Technology

[0002] Respiratory syncytial virus (RSV) is a virus that primarily affects children and the elderly, often causing severe lower respiratory tract infections such as bronchitis and pneumonia. Millions of children worldwide are infected with RSV each year, resulting in numerous hospitalizations and deaths. The RSV genome is a single-stranded negative-sense RNA, approximately 15,000 nucleotides in length, containing ten genes and encoding eleven proteins. Due to the high transmissibility and severe health impacts of RSV, studying its genomic structure and variability is crucial for controlling and preventing RSV infection.

[0003] In recent years, whole-genome sequencing technology has made significant progress, enabling detailed analysis of the genomes of viruses such as RSV. Next-Generation Sequencing (NGS) has been widely used in RSV genome research, providing data with high coverage and accuracy. Despite the many advantages NGS technology has shown in respiratory syncytial virus (RSV) whole-genome sequencing, several challenges remain. The accuracy and completeness of high-throughput sequencing data depend on various factors in sample preparation and data processing. To improve sequencing accuracy, researchers typically need to perform high-coverage sequencing and combine it with bioinformatics tools for rigorous quality control and subsequent analysis. However, due to the high variability and complex genomic structure of the RSV genome, second-generation sequencing technology may encounter challenges in assembling the complete genome. To address these issues, researchers have begun exploring third-generation long-read sequencing technologies.

[0004] For whole-genome detection of respiratory syncytial virus, the current common method is to use a second-generation sequencing platform for metagenomic sequencing. This platform has problems such as long sequencing time, short read length, large amount of human genomic DNA contamination in the sequencing results, high sequencing data volume, and difficulty in obtaining sequencing results that cover the entire genome.

[0005] With the rise of third-generation sequencing technologies (such as PacBio SMRT and Oxford Nanopore), the accuracy and efficiency of respiratory syncytial virus (RSV) whole-genome sequencing have been further improved. Third-generation sequencing technologies can read longer DNA fragments, reduce the complexity of sequence assembly, and have unique advantages in detecting genomic structural variations.

[0006] The existing technology CN116200537A reports the use of third-generation sequencing technology to detect respiratory syncytial virus (RSV) type A, achieving 100% coverage with an average sequencing depth ranging from 1073.26X to 4796.85X. However, this existing technology has the following shortcomings and defects: it requires a very high amount of sequencing data; the distribution of sequencing data in different regions is highly uneven, with significant differences in abundance; there are multiple regions with sequencing depths of 0 or less than 20X; it only covers RSV type A and cannot be universally applied to RSV type B; and it is highly dependent on sample requirements, with samples with Ct values ​​of 25 or 32 exhibiting region missing data. Summary of the Invention

[0007] To overcome the defects and shortcomings of the existing technologies, such as uneven distribution of sequencing data, the present invention provides a method, primers and kits for whole genome sequencing of respiratory syncytial virus.

[0008] The technical solution of the present invention is as follows:

[0009] A method for whole-genome sequencing of respiratory syncytial virus, comprising the following steps:

[0010] S1. The first round of amplification was performed using the first-round amplification primers with the sequences shown in SEQ ID NO.1 to SEQ ID NO.35 in Table 1 as a template for respiratory syncytial virus cDNA.

[0011] S2. Using the second-round amplification primers with the sequences shown in SEQ ID NO.36 to SEQ ID NO.227 in Table 2, a second-round amplification was performed using the first-round amplification product as a template.

[0012] 2. The method for whole genome sequencing of respiratory syncytial virus according to claim 1, characterized in that it further includes the following step: S3. Sequencing adapter ligation.

[0013] The method for whole genome sequencing of respiratory syncytial virus further includes the following step: S4. Sequencing on a machine.

[0014] Reverse transcription is required before S1; the reverse transcription system includes: 2.5 pg to 5 ng / μl nucleic acid, 500 mM M KCl, 100 mM Tris HCl, 250 mM MgCl2, 10 mM dNTP, 10 U / μl reverse transcriptase, 80 nM random primers, 10 μM syncytial virus-specific reverse transcription primers, and water;

[0015] Preferably, the reaction conditions for reverse transcription include: 37℃ for 20 min, 85℃ for 5 s;

[0016] Preferably, the syncytial virus-specific reverse transcription primers have sequences as shown in SEQ ID NO.228 and SEQ ID NO.229;

[0017] Preferably, the system for the first round of amplification includes: 2.5 pg to 5 ng / μl template, 500 mM KCl, 100 mM Tris HCl, 250 mM MgCl2, 10 mM dNTP, 5 U / μl Taq polymerase, 10 μM first round amplification primers, and water;

[0018] Preferably, the template refers to: reverse transcription product;

[0019] Preferably, the reaction program for the first round of amplification includes: 95℃ for 3 min; with 98℃ for 20 s, 60℃ for 2 min, and 65℃ for 3 min as one cycle, for a total of 30 cycles;

[0020] Preferably, the system for the second round of amplification includes: 0.0025–0.5 μl / μl of the first round amplification product, 500 mM MgCl2, 100 mM Tris HCl, 250 mM MgCl2, 10 mM dNTP, 5 U / μl Taq polymerase, 10 μM of the second round amplification primers, and water;

[0021] Preferably, the reaction program for the second round of amplification includes: 95℃ for 2 min; a cycle consisting of 98℃ for 20 s, 60℃ for 1 min, and 65℃ for 2 min, for a total of 6 cycles; and 72℃ for 5 min.

[0022] Preferably, the 5' end of the second round primer has a phosphorylation modification.

[0023] The sequencing adapter ligation includes: ligation reaction after magnetic bead purification;

[0024] Preferably, the ligation reaction system comprises: 1-10 ng / μl of second-round amplification product, 50 mM MgCl2, 5 mM ATP, 50 mM DTT, 250 mM Tris-HCl, 400 U / μl of T4 ligase, and 0.03 μl / μl of sequencing adapter;

[0025] Preferably, the connection reaction is performed at 25°C for 10 minutes.

[0026] The above refers to the process of placing the ligation product in a Nanopore sequencer for sequencing.

[0027] A primer set for whole-genome sequencing of respiratory syncytial virus, comprising a first-round amplification primer and a second-round amplification primer; the first-round amplification primer having sequences shown in SEQ ID NO.1 to SEQ ID NO.93; and the second-round amplification primer having sequences shown in SEQ ID NO.94 to SEQ ID NO.285.

[0028] The 5' end of the second primer has a phosphorylation modification.

[0029] A kit for whole-genome sequencing of respiratory syncytial virus (RSV) includes a primer set for RSV whole-genome sequencing.

[0030] The kit for whole genome sequencing of respiratory syncytial virus further includes: amplification reagents and ligation reagents;

[0031] Preferably, the amplification reagents include: KCl, Tris HCl, MgCl2, dNTPs, Taq polymerase, and water;

[0032] Preferably, the ligation reagents include: purified magnetic beads, MgCl2, ATP, DTT, Tris-HCl, T4 ligase, and sequencing adapters.

[0033] The beneficial effects of this invention are as follows:

[0034] This invention, based on third-generation sequencing technology, develops a method, primer set, and reagent kit for whole-genome sequencing of respiratory syncytial virus (RSV), resulting in a clearer and more complete panoramic view of the RSV genome. The invention provides a set of long-fragment multiplex amplification targeted enrichment primers for RSV types I and II, along with a multiplex amplification reaction system and a tag sequence addition system. This allows for whole-genome sequencing of RSV within 10 hours, achieving full-coverage assembly, tracing, and typing of the virus. It can effectively enrich the whole-genome sequence of RSV from clinical samples, effectively solving the problems of RSV typing and tracing. The detection method of this invention has the following advantages:

[0035] 1. A universal respiratory syncytial virus (RSV) whole genome-specific targeting primer design method based on various RSV types and a RSV whole genome sequencing kit developed based on the method, which can complete the detection of RSV whole genome in 10 hours;

[0036] 2. When using multiple primers designed based on this method for detection, there is no need to remove human genomic DNA during sample extraction. The DNA and RNA extracted using conventional automated instruments such as magnetic beads can meet the requirements for subsequent library construction and sequencing.

[0037] 3. This method has extremely high sensitivity and can be applied to the whole genome sequencing of clinical samples with respiratory syncytial virus Ct values ​​as high as 35;

[0038] 4. During amplification, the universal sequence is added to the target band by multiplex amplification with low concentration of specific primers in the first round. Then, universal barcode primers and common rapid amplification enzymes are added directly for amplification, which can quickly complete the construction of a library of the respiratory syncytial virus whole genome.

[0039] 5. An additional phosphorylation modification was added to the 5' end of the barcode used. The rapid amplification enzyme used during amplification will add an additional A to the extension end. The resulting amplification product can be directly ligated to the sequencing adapter via TA, which greatly simplifies the library preparation steps and shortens the experimental time.

[0040] 6. By using a long-read third-generation sequencing platform, the amplified long fragment data can be simply spliced ​​to obtain the whole genome sequence of respiratory syncytial virus, which can greatly improve the stability of respiratory syncytial virus type determination.

[0041] 7. By adding specific reverse transcription primers for respiratory syncytial virus to the reverse transcription system, the integrity of the syncytial virus in the 3' terminal region can be effectively improved.

[0042] 8. Compared with the sequencing methods in the existing technical references, the primers designed in this invention are universal primers for respiratory syncytial virus (RSV). One set of primers can be used to complete the sequencing of RSV type I and II, while the methods in the literature require the use of multiple sets of primers for different types.

[0043] 9. The universal primers designed in this invention amplify fragments with an average size of around 800 bp, taking into account the amplification performance of all fragments and maintaining good uniformity of amplified fragment coverage. In contrast, methods in the literature amplify fragments up to 4KB in size, making amplification very difficult and unable to achieve effective whole-genome enrichment. The method of this invention has a wide coverage and can be adapted to all respiratory syncytial virus types, all of which can be sequenced for whole genome.

[0044] The method of this invention is applicable to various clinical sample types such as conventional swabs and bronchoalveolar lavage fluid. There is no need to remove human genomic DNA during sample extraction. The DNA extracted using conventional automated instruments such as magnetic beads can meet the requirements for subsequent library construction and sequencing.

[0045] The method of this invention optimizes and adjusts the multiplex amplification system, enabling whole-genome sequencing even when the Ct value of respiratory syncytial virus in the original nucleic acid sample reaches 35. It is an ultra-sensitive genome sequencing method.

[0046] This invention designs specific primers for the detection target and adds a universal sequence to the 5' end of the primers. This allows for the amplification and enrichment of respiratory syncytial virus while simultaneously adding the universal sequence to the amplified target band. The library for sequencing can then be obtained by directly adding universal barcode primers and amplifying with a common rapid amplification enzyme.

[0047] This invention optimizes the multiplex amplification system conditions multiple times. With the optimized amplification primers, the proportion of respiratory syncytial virus (RSV) data in the sequencing data can reach more than 80% without removing human genomic DNA, thus solving the problem of human genomic DNA contamination in the whole genome detection of RSV.

[0048] This invention utilizes a long-read third-generation sequencing platform, where amplified long fragment data only requires simple splicing to directly obtain whole-genome data. The average length of the sequencing data obtained by this method is 0.8kb, which greatly improves the uniformity of respiratory syncytial virus coverage compared to the short read length of the second-generation platform. Attached Figure Description

[0049] Figure 1 A flowchart illustrating the experimental principle of a sequencing method provided in a specific embodiment of the present invention.

[0050] Figure 2 This is a distribution diagram of the sequencing data of two samples from Experimental Example 1 of the present invention.

[0051] Figure 3 This is a genome coverage distribution map of Experiment 2 of the present invention, which was sequenced under one round of non-purification conditions of 0.5 μl, 1 μl, and 2.5 μl, respectively, where A to C correspond to 0.5 μl, 1 μl, and 2.5 μl, respectively.

[0052] Figure 4 This is a distribution map of the average coverage of respiratory syncytial virus under different conditions (Ct values ​​of 35, 30, and 25) in Experiment 3 of the present invention, where A to C correspond to Ct values ​​of 35, 30, and 25, respectively.

[0053] Figure 5 This is a genome coverage distribution map of respiratory syncytial virus sequencing using different methods in Experiment 4 of this invention. AB represents the method in the references, and CD represents the method of this invention. Detailed Implementation

[0054] The following detailed description of the present invention, in conjunction with the accompanying drawings, specific experimental examples, and experimental cases, does not limit the scope of protection of the present invention.

[0055] Sources of biomaterials

[0056] All respiratory syncytial virus (RSV) positive swab samples used in Experiments 1 through 4 were obtained from Peking Union Medical College Hospital, Chinese Academy of Medical Sciences.

[0057] Group 1 Examples, Sequencing Method of the Present Invention

[0058] This set of embodiments provides a method for whole-genome sequencing of respiratory syncytial virus (RSV). All embodiments in this set share the following common feature: the method for whole-genome sequencing of RSV includes the following steps:

[0059] S1. The first round of amplification was performed using the first-round amplification primers with the sequences shown in SEQ ID NO.1 to SEQ ID NO.35 in Table 1 as a template for respiratory syncytial virus cDNA.

[0060] S2. Using the second-round amplification primers with the sequences shown in SEQ ID NO.36 to SEQ ID NO.227 in Table 2, a second-round amplification was performed using the first-round amplification product as a template.

[0061] Those skilled in the art, based on the descriptions and teachings of this invention, can perform whole-genome sequencing, typing, and tracing of respiratory syncytial virus (RSV) by employing steps S1 and S2 as described above, combined with common experimental procedures in the field of molecular biology, such as those described in *Molecular Cloning: A Laboratory Manual*, and known sequencing operations. Any act of sequencing, typing, and tracing the whole genome of RSV using the above steps falls within the scope of protection of this invention.

[0062] In a further embodiment, the method for whole genome sequencing of respiratory syncytial virus further includes the following step: S3. Sequencing adapter ligation.

[0063] In a further embodiment, the method for whole genome sequencing of respiratory syncytial virus further includes the following step: S4. Sequencing on a machine.

[0064] In some embodiments, reverse transcription is performed before S1; the reverse transcription system includes: 2.5 pg to 5 ng / μl nucleic acid, 500 mM KCl, 100 mM Tris HCl, 250 mM MgCl2, 10 mM dNTP, 10 U / μl reverse transcriptase, 80 nM random primers, 10 μM syncytial virus-specific reverse transcription primers, and water;

[0065] Preferably, the reaction conditions for reverse transcription include: 37℃ for 20 min, 85℃ for 5 s;

[0066] Preferably, the syncytial virus-specific reverse transcription primers have sequences as shown in SEQ ID NO.228 and SEQ ID NO.229;

[0067] Preferably, the system for the first round of amplification includes: 2.5 pg to 5 ng / μl template, 500 mM KCl, 100 mM Tris HCl, 250 mM MgCl2, 10 mM dNTP, 5 U / μl Taq polymerase, 10 μM first round amplification primers, and water;

[0068] Preferably, the template refers to: reverse transcription product;

[0069] Preferably, the reaction program for the first round of amplification includes: 95℃ for 3 min; with 98℃ for 20 s, 60℃ for 2 min, and 65℃ for 3 min as one cycle, for a total of 30 cycles;

[0070] Preferably, the system for the second round of amplification includes: 0.0025–0.5 μl / μl of the first round amplification product, 500 mM MgCl2, 100 mM Tris HCl, 250 mM MgCl2, 10 mM dNTP, 5 U / μl Taq polymerase, 10 μM of the second round amplification primers, and water;

[0071] Preferably, the reaction program for the second round of amplification includes: 95℃ for 2 min; a cycle consisting of 98℃ for 20 s, 60℃ for 1 min, and 65℃ for 2 min, for a total of 6 cycles; and 72℃ for 5 min.

[0072] Preferably, the 5' end of the second round primer has a phosphorylation modification.

[0073] In a specific embodiment, the sequencing adapter ligation includes: ligation reaction after magnetic bead purification;

[0074] Preferably, the ligation reaction system comprises: 1-10 ng / μl of second-round amplification product, 50 mM MgCl2, 5 mM ATP, 50 mM DTT, 250 mM Tris-HCl, 400 U / μl of T4 ligase, and 0.03 μl / μl of sequencing adapter;

[0075] Preferably, the connection reaction is performed at 25°C for 10 minutes.

[0076] In a more specific embodiment, the sequencing on the instrument refers to placing the ligation product in a Nanopore sequencer for sequencing.

[0077] Group 2 Examples, Primer Set of the Present Invention

[0078] This set of embodiments provides a primer set for whole-genome sequencing of respiratory syncytial virus (RSV). This set of embodiments shares the following common features: the primer set for whole-genome sequencing of RSV includes a first-round amplification primer and a second-round amplification primer; the first-round amplification primer has the sequences shown in SEQ ID NO. 1 to SEQ ID NO. 35; the second-round amplification primer has the sequences shown in SEQ ID NO. 36 to SEQ ID NO. 227.

[0079] Those skilled in the art, based on the descriptions and teachings of this invention, can achieve whole-genome sequencing, typing, and tracing of respiratory syncytial virus (RSV) using primers with sequences shown in SEQ ID NO. 1 to SEQ ID NO. 227, combined with common experimental procedures in molecular biology, such as those described in *Molecular Cloning: A Laboratory Manual* and known sequencing operations. Any synthesis, amplification, reaction, preparation, or production of primers with sequences shown in SEQ ID NO. 1 to SEQ ID NO. 227 falls within the scope of protection of this invention.

[0080] In a specific embodiment, the 5' end of the second round primer is phosphorylated.

[0081] Group 3 Examples, the reagent kit of the present invention

[0082] This set of embodiments provides a kit for whole-genome sequencing of respiratory syncytial virus (RSV). These embodiments share the following common feature: the kit for whole-genome sequencing of RSV includes a primer set for whole-genome sequencing of RSV as described in any of the embodiments in the second set.

[0083] Any act of placing a primer set for respiratory syncytial virus whole genome sequencing as described in any of the embodiments of Group 2, or primers having the sequences shown in SEQ ID NO. 1 to SEQ ID NO. 227, into a product packaging box, and / or any act of synthesizing, amplifying, reacting, preparing, or producing primers having the sequences shown in SEQ ID NO. 1 to SEQ ID NO. 227 and placing them into a product packaging box, falls within the protection scope of this invention.

[0084] In a further embodiment, the kit for whole genome sequencing of respiratory syncytial virus further includes: amplification reagent and ligation reagent;

[0085] Preferably, the amplification reagents include: KCl, Tris HCl, MgCl2, dNTPs, Taq polymerase, and water;

[0086] Preferably, the ligation reagents include: purified magnetic beads, MgCl2, ATP, DTT, Tris-HCl, T4 ligase, and sequencing adapters.

[0087] In one specific embodiment of the present invention, a set of primers applicable to the amplification of large fragment universal sequences of all respiratory syncytial virus (RSV) types was developed. These primers are used to specifically amplify and enrich the whole genome nucleic acid fragments of RSV derived from clinical samples such as swabs and bronchoalveolar lavage fluid. The assembly and typing of the entire RSV genome can be completed in 10 hours. Compared with conventional NGS detection technology, this method can effectively achieve RSV recombination, cover the entire RSV genome, and maintain good amplification uniformity.

[0088] This method eliminates the need for removal of human genomic DNA during extraction. DNA extracted using conventional automated instruments such as magnetic beads is sufficient for subsequent library construction and sequencing. It is particularly suitable for sample types with high human genomic DNA content, such as swabs and bronchoalveolar lavage fluid. Detection can be completed with a total DNA extraction volume of 50 pg or more. Compared with conventional respiratory syncytial virus sequencing procedures, it can significantly improve the success rate of library construction for trace samples.

[0089] This invention designs specific primers for the detection target and adds a universal sequence to the 5' end of the primers, which can achieve simultaneous coverage of the entire genome of respiratory syncytial virus. By detecting samples with different Ct values, it can be surprisingly found that this method can also achieve good whole genome coverage for clinical samples with Ct values ​​as high as 35.

[0090] In primer design, this invention first downloads all corresponding respiratory syncytial virus (RSV) reference genome sequences based on different RSV types. After truncating the genome sequences to 30 bp, sequence universality is assessed. Conserved gene regions are selected as target regions for primer design after genome consistency alignment. During amplification, multiplex amplification is performed using specific primers in the first round, and the universal sequence is added to the amplified target product. The first-round amplification product can be purified or directly added to universal tag sequence primers and a common rapid amplification Taq enzyme. This avoids severe amplification bias caused by differences in amplification efficiency between different primers, resulting in a more uniform distribution of sequencing sequence numbers across different regions. Furthermore, this invention adds an additional phosphorylation modification to the 5' end of the tag sequence used. The rapid amplification Taq enzyme used during amplification adds an additional A base to the extension end. Therefore, the resulting amplification product does not require end repair with A addition and phosphorylation, and can be directly ligated to sequencing adapters via TA, greatly simplifying the library construction process and shortening the experimental time.

[0091] This invention optimizes the multiplex amplification system conditions through multiple rounds of testing. The optimized primers, without removing human genomic DNA, achieve a respiratory syncytial virus (RSV) concentration of over 90% in the sequencing data, solving the problem of human genomic DNA contamination in RSV whole-genome detection. Furthermore, by using a long-read third-generation sequencing platform, the amplified long-fragment data can be easily assembled to directly obtain the entire RSV genome sequence, which can be used for subsequent RSV typing and etiological analysis.

[0092] The average length of the sequencing data obtained using this method is 0.8k, which is more than 5 times longer than the PE150 standard used in second-generation mNGS platforms, greatly improving the accuracy and stability of pathogen identification. Furthermore, it maintains a high degree of consistency in the selection of target fragment sizes, enhancing the sensitivity of respiratory syncytial virus whole-genome sequencing by controlling the amplified fragment length while considering fragment length.

[0093] A detailed implementation flow of the method provided in a specific embodiment of the present invention is as follows: Figure 1 As shown, the specific operation is as follows:

[0094] 1. Synthesis of primers for the whole genome of respiratory syncytial virus

[0095] Based on the 800bp targeted amplification fragment length, the respiratory syncytial virus genome comprises 14 regions. The designed universal sequence and primer sequences are shown in Table 1 below:

[0096] Table 1

[0097]

[0098]

[0099] The number following RSV_MD corresponds to the region amplified by respiratory syncytial virus (RSV). The F-terminal and R-terminal primers following the number are a pair of specific target primers used to specifically amplify and enrich the corresponding target region. In specific experiments, one or more primers in combination can be selected for multiplex amplification depending on the experimental objective. Primers can be synthesized by primer synthesis companies, such as Shanghai Sangon Biotech.

[0100] 4. Universal tag sequence primer design

[0101] The universal tag sequence consists of three parts: a tag sequence at the 5' end to identify the start sequence, a 24 bp tag sequence, and a universal primer sequence at the 3' end. The 5' end of the sequence undergoes additional phosphorylation modification, and the 96 tag sequences exhibit significant differences, facilitating segmentation and identification.

[0102] 5. Synthesis of universal tag sequence primers

[0103] The tag sequences designed based on the above primer design principles are shown in Table 2 below:

[0104] Table 2

[0105]

[0106]

[0107]

[0108]

[0109]

[0110] The primer set following PMGIB, with its numerical code, is a group of tag sequence primers used to add tag sequences to specific amplification enrichment target regions. In specific experiments, one or more combinations can be selected for multiplex amplification depending on the experimental objective. Primers can be synthesized by primer synthesis companies, such as Shanghai Sangon Biotech.

[0111] 6. Nucleic acid extraction from clinical samples

[0112] The principle of this method is based on multiplex targeted enrichment, which can specifically increase the proportion of respiratory syncytial virus in sequencing data. Therefore, there is no need to remove human genomic DNA during extraction. It is suitable for methods that extract DNA and RNA simultaneously. The magnetic bead method of the Mingde automated extraction instrument is recommended for nucleic acid extraction. The extraction method should follow the kit instructions and instrument manual. The extraction time is approximately 0.5 hours.

[0113] 7. Reverse transcription and multiplex PCR amplification using first-round respiratory syncytial virus-specific primers

[0114] To obtain the complete genome sequence, especially the 5' end of the RNA virus, this protocol uses not only random primers but also specific reverse transcription primers. The specific reverse transcription primers used are shown in Table 3 below:

[0115] Table 3

[0116] SEQ ID NO. Primer name Sequence (5' to 3') 228 PMGIB01-F AGTGTCAAAAACTAA 229 PMGIB01-R ACGAGAAAAAAAGTGTC

[0117] The specific reverse transcription system is shown in Table 4 below:

[0118] Table 4

[0119]

[0120] The random primers in Table 4 above have the common technical meaning known to those skilled in the art, specifically referring to: random primers with 6 bases NNNNNN, where N represents one of the random bases ATCG.

[0121] After mixing the prepared reaction mixture thoroughly, centrifuge briefly and then perform the amplification reaction on a PCR instrument:

[0122]

[0123] After reverse transcription is complete, a subsequent round of amplification can be performed directly, or the sample can be purified with 1X magnetic beads before another round of amplification.

[0124] The specific primers for the first round of amplification consist of two parts. The first part is a universal sequence located at the 5' end. The introduction of this sequence is because the universal sequence is used as the primer binding site during the second round of amplification, so that all samples can be amplified using the same set of primers. The second part is a respiratory syncytial virus-specific primer located at the 3' end. This primer specifically binds to a specific region of respiratory syncytial virus, which can specifically enrich this part of the target region to be sequenced.

[0125] Respiratory syncytial virus (RSV) primers were uniformly and quantitatively diluted to 10 μM, then mixed in equal volumes and used as RSV-specific primers for the first round of amplification.

[0126] The general preparation system for the first round of amplification reaction is shown in Table 5 below:

[0127] Table 5

[0128]

[0129]

[0130] After mixing the prepared reaction mixture thoroughly, centrifuge briefly and then perform the amplification reaction on a PCR instrument:

[0131]

[0132] The first round of amplification takes approximately 180 minutes.

[0133] 8. Second round of PCR amplification reaction with tagged sequence

[0134] The amplification products from the first round were purified using 0.55X magnetic beads, and the purified products could be directly used for the second round of amplification.

[0135] Alternatively, the product of the first-round PCR reaction can be used directly as a template. Take 0.5-5 μl of the reaction reagents prepared below and add them to perform the second round of tagged sequence amplification. The preparation system is shown in Table 6 below:

[0136] Table 6

[0137]

[0138] After mixing the prepared reaction mixture thoroughly, centrifuge briefly and then perform the amplification reaction on a PCR instrument:

[0139]

[0140] The second round of amplification takes approximately 30 minutes.

[0141] The tagged primers used in this procedure are all phosphorylated at the 5' end. The F end and R end of the tagged primer sequence form a pair. Each sample is amplified using a pair of tagged primers, and different samples use different tagged primers. During sequencing, different samples can be directly separated based on the tagged primers.

[0142] 9. Perform sequencing adapter ligation.

[0143] The second-round amplification products were purified using standard 1X purification magnetic beads. Refer to the instruction manual for specific procedures; Mindray purification magnetic beads are recommended. After purification, the Qubit concentration was determined. Equal volumes of samples to be sequenced in the same batch were mixed, with a total volume of 50–500 ng for subsequent ligation reactions.

[0144] The configuration of the connection system is shown in Table 7 below:

[0145] Table 7

[0146]

[0147]

[0148] After mixing the prepared reaction mixture, briefly centrifuge and ligate at 25°C for 10 minutes. After the reaction, ligate the sequencing adapter. The ligation product is then processed using the Nanopore official sequencing protocol. The ligation and sequencing process takes approximately 0.5 hours.

[0149] 10. Sequencing and Data Analysis

[0150] The sequencing data is analyzed simultaneously using Mindray analysis software or other software. The complete genome sequence of respiratory syncytial virus (RSV) can be detected after 2–8 hours of sequencing. Refer to the software user manual for specific analysis procedures. Other software includes ARTIC software or MetaSPAdes.

[0151] Experiment Example 1: Sequencing of the whole genome of respiratory syncytial virus using magnetic beads for purification.

[0152] One positive swab sample each for respiratory syncytial virus (RSV) type I and II was collected. After one round of amplification, the amplification products were purified using 0.55X magnetic beads. Finally, library construction and sequencing were performed according to standard operating procedures. All two samples were assembled into complete RSV genome sequences. The specific distribution of the two samples is as follows: Figure 2 As shown: Figure 2 A is type I. Figure 2 B is type II. Figure 2 A and Figure 2 The peak value, average value, and relative variability (CV) of each sample are shown in Table 8 below, which is sufficient to prove that the detection method of the present invention has excellent uniformity for respiratory syncytial virus sequencing and typing:

[0153] Table 8

[0154] Drawing number RSV01 RSV02 RSV03 RSV04 RSV05 RSV06 RSV07 RSV08 RSV09 RSV10 RSV11 RSV12 RSV13 RSV14 average value CV value Figure 2 A 397 412 421 419 428 423 431 427 429 413 418 421 424 422 420 2% Figure 2 B 389 409 412 408 411 417 429 421 428 415 431 424 429 421 417 3%

[0155] Example 2: Directly adding the first round of amplification products to perform tag sequence amplification and respiratory syncytial virus whole genome sequencing.

[0156] Two respiratory syncytial virus (RSV) positive swab samples were collected. After the first round of amplification, without magnetic bead purification, 2.5 μl, 1 μl, and 0.5 μl of the amplification product were directly added to the second round of amplification system for further amplification. Finally, library construction and sequencing were performed according to standard operating procedures. RSV whole genome sequences were obtained from all three samples under different conditions. The average RSV coverage under different conditions (0.5 μl, 1 μl, 2.5 μl) is shown below. Figure 3 As shown in A to 3C. Figure 3 The peak values, average values, and relative variability (CV) of samples A through 3C are shown in Table 9 below:

[0157] Table 9

[0158] Drawing number RSV01 RSV02 RSV03 RSV04 RSV05 RSV06 RSV07 RSV08 RSV09 RSV10 RSV11 RSV12 RSV13 RSV14 average value CV value Figure 3 A 400 403 411 409 415 410 414 409 412 406 413 412 421 418 411 1% Figure 3 B 400 421 415 321 36 145 483 415 416 414 413 417 402 409 365 32% Figure 3 C 11 47 234 393 415 89 217 410 121 413 375 391 58 189 240 63%

[0159] Example 3: Whole genome sequencing of respiratory syncytial virus under different Ct values

[0160] Two respiratory syncytial virus (RSV) positive swab samples were collected. After RSV Ct value detection using qPCR, the samples were serially diluted to Ct values ​​of 25, 30, and 35 before RSV whole-genome sequencing. RSV whole-genome sequences were obtained from both samples under all different conditions. The average RSV coverage under different conditions (Ct values ​​of 35, 30, and 25) is shown below. Figure 4 As shown in A to 4C. Figure 4 The peak values, average values, and relative variability (CV) of samples A through 4C are shown in Table 10 below:

[0161] Table 10

[0162]

[0163]

[0164] Example 4: Comparison of whole-genome sequencing protocol for respiratory syncytial virus samples with the method in Reference 2

[0165] Two respiratory syncytial virus (RSV) positive swab samples of different types were collected. After RSV Ct value detection using qPCR, the sample distribution was analyzed for RSV whole-genome sequencing according to the method of this invention and the method in Reference 2. RSV whole-genome sequences were obtained from both samples using the method of this invention. The prior art reference is "Xiaomin Dong, Yi-Mo Deng, Ammar Aziz, Paμl Whitney, Jμlia Clark, Patrick Harris, Catherine Bautista, Anna-Maria Costa, Gregory Waller, Andrew J Daley, Megan Wieringa, Tony Korman, Ian G. Barr, A simplified, amplicon-based method for whole genome sequencing of human respiratory syncytial viruses, Journal of Clinical Virology, Volume 161, 2023, 105423, ISSN".

[0166] The method described in 1386-6532, https: / / doi.org / 10.1016 / j.jcv.2023.105423, can only achieve coverage of a partial area. Specific coverage depends on factors such as... Figure 5 As shown, Figure 5 AB is the method used in the references to sequence the genome coverage distribution of respiratory syncytial virus. Figure 5 CD is a genome coverage distribution map of respiratory syncytial virus sequencing using the method of this invention. Figure 5 The peak value, mean value, and relative variability (CV) of each sample from A to 5D are shown in Table 11 below:

[0167] Table 11

[0168] Drawing number RSV01 RSV02 RSV03 RSV04 RSV05 RSV06 RSV07 RSV08 RSV09 RSV10 RSV11 RSV12 RSV13 RSV14 average value CV value Figure 5 A 46 48 121 114 21 11 8 3 53 47 24 10 89 131 52 83% Figure 5 B 41 212 239 187 20 16 8 2 59 40 11 3 89 125 75 106% Figure 5 C 400 403 404 402 401 400 403 397 401 402 403 405 407 406 402 1% Figure 5 D 401 408 415 411 41 353 513 421 417 409 414 403 415 406 388 26% .

Claims

1. A method for whole-genome sequencing of respiratory syncytial virus, characterized in that, Includes the following steps: S1. The first round of amplification was performed using respiratory syncytial virus cDNA as a template, using the first-round amplification primers shown in SEQ ID NO.1 to SEQ ID NO.35; S2. Using the second-round amplification primers shown in SEQ ID NO.36~SEQ ID NO.227, a second-round amplification is performed using the first-round amplification product as a template; S3. Sequencing adapter ligation; S4. Sequencing; The 5' end of the second round of amplification primers has phosphorylation modification; The sequencing was third-generation sequencing.

2. The method for whole-genome sequencing of respiratory syncytial virus according to claim 1, characterized in that, Reverse transcription is required before S1; the reverse transcription system includes: 2.5 pg ~ 5 ng / μl nucleic acid, 500 mM KCl, 100 mM Tris HCl, 250 mM MgCl2, 10 mM dNTP, 10 U / μl reverse transcriptase, 80 nM random primers, 10 μM syncytial virus-specific reverse transcription primers, and water; And / or, the reaction conditions for the reverse transcription include: 37°C for 20 min, 85°C for 5 s; And / or, the syncytial virus-specific reverse transcription primers have sequences as shown in SEQ ID NO.228 and SEQ ID NO.229; And / or, the system for the first round of amplification includes: 2.5 pg ~ 5 ng / μl template, 500 mM KCl, 100 mM TrisHCl, 250 mM MgCl2, 10 mM dNTP, 5 U / μl Taq polymerase, 10 μM first round amplification primers and water; And / or, the reaction program for the first round of amplification includes: 95℃ for 3 min; with 98℃ for 20 s, 60℃ for 2 min, and 65℃ for 3 min as one cycle, for a total of 30 cycles; And / or, the system for the second round of amplification includes: 0.0025~0.5 μl / μl of the first round amplification product, 500 mM KCl, 100 mM Tris HCl, 250 mM MgCl2, 10 mM dNTP, 5 U / μl Taq polymerase, 10 μM of the second round amplification primers, and water; And / or, the reaction program for the second round of amplification includes: 95℃ for 2 min; 6 cycles consisting of 98℃ for 20 s, 60℃ for 1 min, and 65℃ for 2 min; and 72℃ for 5 min.

3. The method for whole-genome sequencing of respiratory syncytial virus according to claim 2, characterized in that, The template is a reverse transcription product.

4. The method for whole-genome sequencing of respiratory syncytial virus according to claim 1, characterized in that, The sequencing adapter ligation includes: ligation reaction after magnetic bead purification; And / or, the ligation reaction system comprises: 1-10 ng / μl of second-round amplification product, 50 mM MgCl2, 5 mM ATP, 50 mM DTT, 250 mM Tris-HCl, 400 U / μl of T4 ligase, and 0.03 μl / μl of sequencing adapter; And / or, the conditions for the connection reaction are 25°C for 10 min.

5. The method for whole-genome sequencing of respiratory syncytial virus according to claim 1, characterized in that, The above refers to the process of placing the ligation product in a Nanopore sequencer for sequencing.

6. A primer set for whole-genome sequencing of respiratory syncytial virus, characterized in that, It includes a first-round amplification primer and a second-round amplification primer; the first-round amplification primer is the sequence shown in SEQ ID NO.1 to SEQ ID NO.93; the second-round amplification primer is the sequence shown in SEQ ID NO.94 to SEQ ID NO.285; the 5' end of the second-round amplification primer has phosphorylation modification; the sequencing is third-generation sequencing.

7. A kit for whole-genome sequencing of respiratory syncytial virus, characterized in that, Includes a primer set for whole genome sequencing of respiratory syncytial virus as described in claim 6.

8. A kit for whole-genome sequencing of respiratory syncytial virus according to claim 7, characterized in that, It also includes: amplification reagents and ligation reagents; The amplification reagents include: KCl, Tris HCl, MgCl2, dNTPs, Taq polymerase, and water; And / or, ligation reagents include: purified magnetic beads, MgCl2, ATP, DTT, Tris-HCl, T4 ligase, and sequencing adapters.

Citation Information

Patent Citations

  • Rapid identification method for 23 respiratory tract RNA viruses based on nanopore sequencer

    CN113430303A

  • Rapid pathogenic microorganism detection method and kit thereof

    CN114196743A

  • Respiratory syncytial virus A type whole genome sequencing method

    CN116200537A